CKPTのチャート
CKPTの企業情報
| symbol | CKPT |
|---|---|
| 会社名 | Checkpoint Therapeutics Inc （チェックポイント・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Checkpoint Therapeutics Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition development and commercialization of non-chemotherapy immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1) glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral small molecules targeted anti-cancer agents consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations an inhibitor of the bromodomain and extra-terminal (BET) protein BRD4 and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103. チェックポイント・セラピュ―ティクスは米国のバイオ医薬品企業。主にがん腫瘍を治療するための非化学療法や免疫療法の開発・商業化に従事する。認可された同社の抗体ポ―トフォリオには、グルココルチコイド誘発TNFR関連タンパク質および炭酸脱水酵素を標的とする抗体が含まれる。また、経口抗がん療法も開発する。本社所在地はニューヨーク。 Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma intended to support one or more applications for marketing approval. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor ('EGFR') inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc. |
| 本社所在地 | 2 Gansevoort Street 9th Floor New York NY 10014 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 212-554-4366 |
| 設立年月日 | 41944 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.checkpointtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ckpt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -27.35000 |
| 終値（lastsale） | 3.32 |
| 時価総額（marketcap） | 106598108.48 |
| 時価総額 | 時価総額（百万ドル） 89.25986 |
| 売上高 | 売上高（百万ドル） 1.15100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 60.95586 |
| 当期純利益 | 当期純利益（百万ドル） -27.25000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Checkpoint Therapeutics Inc revenues decreased 55% to $470K. Net loss increased 42% to $15.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancin increase of 76% to $12.1M (expense) General and administrative - Balanci increase of 53% to $2.6M (expense). |
CKPTのテクニカル分析
CKPTのニュース
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference 2022/05/19 12:30:00 GlobeNewswire
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference.
CKPT stock gains on key regulatory milestone in Europe (NASDAQ:CKPT) 2022/05/13 15:59:01 Seeking Alpha
The shares of clinical-stage biotech Checkpoint Therapeutics (CKPT) are trading sharply higher on Friday as H.C
Checkpoint Therapeutics GAAP EPS of -$0.20 2022/05/12 20:50:08 Seeking Alpha
Checkpoint Therapeutics press release (CKPT): Q1 GAAP EPS of -$0.20.As of March 31, 2022, Checkpoint’s cash and cash equivalents totaled $41.5 million, compared to $54.7 million…
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights 2022/05/12 20:30:00 GlobeNewswire
Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022
Checkpoint: Potential Upside Based On Marketing Application (NASDAQ:CKPT) 2022/04/18 18:15:52 Seeking Alpha
Checkpoint is a speculative biotech play to look into, because the company remains heavily undervalued based on recent progress. See more on CKPT stock here.
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities 2022/04/04 12:15:00 GlobeNewswire
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.
Checkpoint Therapeutics: Q4 Earnings Insights 2022/03/28 12:08:09 Benzinga
Checkpoint Therapeutics (NASDAQ: CKPT ) reported its Q4 earnings results on Monday, March 28, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Checkpoint Therapeutics missed estimated earnings by 160.0%, reporting an EPS of … Full story available on Benzinga.com
Checkpoint Therapeutics GAAP EPS of -$0.75 misses by $0.24, revenue of $0.27M misses by $0.09M 2022/03/28 12:03:39 Seeking Alpha
Checkpoint Therapeutics press release (CKPT): FY GAAP EPS of -$0.75 misses by $0.24.Revenue of $0.27M (-74.8% Y/Y) misses by $0.09M.Shares +3.93% PM.
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights 2022/03/28 11:30:00 GlobeNewswire
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.
Analysts Predict A Surge In Checkpoint Therapeutics Inc. (NASDAQ: CKPT)? 2022/03/11 14:30:00 Stocks Register
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) shares, rose in value on Thursday, 03/10/22, with the stock price up by 13.77% to the previous day’s close as strong demand from buyers drove the stock to $1.90. Actively observing the price movement in the last trading, the stock closed the session at $1.67, falling within a range of $1.61 … Analysts Predict A Surge In Checkpoint Therapeutics Inc. (NASDAQ: CKPT)? Read More »
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference 2021/09/22 12:30:00 Intrado Digital Media
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference. A live webcast of the fireside chat will be available on the Events page, located within the Investors section of Checkpoints website, https://ir.checkpointtx.com/event-calendar/default.aspx , for approximately 30 days following the meeting.
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences 2021/09/09 12:30:00 Intrado Digital Media
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: